BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38397189)

  • 21. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
    Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
    Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.
    Goparaju C; Donington JS; Hsu T; Harrington R; Hirsch N; Pass HI
    J Thorac Oncol; 2013 Sep; 8(9):1203-11. PubMed ID: 23887168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotensin expression and outcome of malignant pleural mesothelioma.
    Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
    Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats.
    Okazaki Y; Chew SH; Nagai H; Yamashita Y; Ohara H; Jiang L; Akatsuka S; Takahashi T; Toyokuni S
    Cancer Sci; 2020 Jun; 111(6):2016-2027. PubMed ID: 32248600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.
    Kim MC; Hwang SH; Kim NY; Lee HS; Ji S; Yang Y; Kim Y
    BMC Cancer; 2018 Aug; 18(1):819. PubMed ID: 30111297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
    Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
    Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
    Abayasiriwardana KS; Wood MK; Prêle CM; Birnie KA; Robinson BW; Laurent GJ; McAnulty RJ; Mutsaers SE
    Biochem Biophys Res Commun; 2019 Mar; 510(2):198-204. PubMed ID: 30685089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
    Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
    Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
    Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
    Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
    Zonca S; Pinton G; Wang Z; Soluri MF; Tavian D; Griffin M; Sblattero D; Moro L
    Cell Death Dis; 2017 Feb; 8(2):e2592. PubMed ID: 28151477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
    Schelch K; Wagner C; Hager S; Pirker C; Siess K; Lang E; Lin R; Kirschner MB; Mohr T; Brcic L; Marian B; Holzmann K; Grasl-Kraupp B; Krupitza G; Laszlo V; Klikovits T; Dome B; Hegedus B; Garay T; Reid G; van Zandwijk N; Klepetko W; Berger W; Grusch M; Hoda MA
    Carcinogenesis; 2018 Apr; 39(4):534-545. PubMed ID: 29635378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues].
    Li B; Pu YQ; Li ZL; Zhao Y; Zi JJ; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul; 40(7):487-494. PubMed ID: 35915937
    [No Abstract]   [Full Text] [Related]  

  • 39. KRAS signaling in malignant pleural mesothelioma.
    Marazioti A; Krontira AC; Behrend SJ; Giotopoulou GA; Ntaliarda G; Blanquart C; Bayram H; Iliopoulou M; Vreka M; Trassl L; Pepe MAA; Hackl CM; Klotz LV; Weiss SAI; Koch I; Lindner M; Hatz RA; Behr J; Wagner DE; Papadaki H; Antimisiaris SG; Jean D; Deshayes S; Grégoire M; Kayalar Ö; Mortazavi D; Dilege Ş; Tanju S; Erus S; Yavuz Ö; Bulutay P; Fırat P; Psallidas I; Spella M; Giopanou I; Lilis I; Lamort AS; Stathopoulos GT
    EMBO Mol Med; 2022 Feb; 14(2):e13631. PubMed ID: 34898002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered protease-activated receptor-1 expression and signaling in a malignant pleural mesothelioma cell line, NCI-H28, with homozygous deletion of the β-catenin gene.
    Fazzini A; D'Antongiovanni V; Giusti L; Da Valle Y; Ciregia F; Piano I; Caputo A; D'Ursi AM; Gargini C; Lucacchini A; Mazzoni MR
    PLoS One; 2014; 9(11):e111550. PubMed ID: 25364818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.